

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 90711

Title: Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen:
Novel viral biomarkers for chronic hepatitis B management

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05469058

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Chief Physician

Reviewer's Country/Territory: China

Author's Country/Territory: Thailand

Manuscript submission date: 2023-12-12

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2024-01-16 15:50

Reviewer performed review: 2024-01-25 20:20

Review time: 9 Days and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Thank you for the opportunity to revise your publication. It is a good study to understand the significance of the kinetics of serum qAnti-HBc and qHBsAg levels in CHB patients. This is an excellent review on the significance of the kinetics of serum qAnti-HBc and qHBsAg levels in CHB patients giving a systematic and detailed picture on this important issue. Some minor points: 1. In page 7 5th line: "Instead of directly interacting with cccDNA, NAs only inhibit HBV DNA" sentence not clear. "inhibit HBV DNA synthesis" 2. In page 18 2th paragraph: the 3rd sentence should read: Using the iTACT-assays, they discovered that 154/418 (36.8%) of the samples obtained following seroclearance had HBsAg. 3. Page 22, the 2nd sentence of the first chapter: "this investigation" can it be explained a bit more? which investigation? 4. Page 22, the last sentence of the first chapter: In reference 80, they aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg-positive patients treated with nucleos(t)ide analogues (NA) in aretrospective analysis. while you pointed out in the article "they deduced that PEG-IFN α -2a-based therapies might attain greater amounts of HBsAg clearance, as measured by qHBsAg and seroconversion, and



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

these treatments posed no risk to inactive HBsAg carriers[80].” Whether the literature was misused?